Three-drug combination remodels immune environment in gastric cancer

November 4, 2026

A triplet combination therapy can remodel the tumor microenvironment in patients with advanced gastric cancer and shows a promising safety profile, according to results from a new phase 2 clinical trial.

Search

RECENT PRESS RELEASES

Asian chip stocks slide as disappointing Qualcomm, Arm earnings weigh

SWI Editorial Staff2026-11-04T20:51:37-08:00November 4, 2026|

FIR against Meta over child sexual abuse material on its platforms

SWI Editorial Staff2026-11-04T20:47:18-08:00November 4, 2026|

Ethereum Price Prediction: Can ETH Hold $2,300 After 7 Days of Fund Selling as Pepeto Buyers Stake?

SWI Editorial Staff2026-11-04T20:45:03-08:00November 4, 2026|

Two U.S. service members accused of smuggling synthetic cannabis into Korea

SWI Editorial Staff2026-11-04T20:44:41-08:00November 4, 2026|

SpaceX Just Picked Qualcomm for Its Own 5G Network. I Still See the Stock as a Hold.

SWI Editorial Staff2026-11-04T20:41:01-08:00November 4, 2026|

Stock market rises after election shifts; ECU professor says gridlock boosts confidence

SWI Editorial Staff2026-11-04T20:40:19-08:00November 4, 2026|